We should see an approval in the EU for Kadcyla in this coming month for pre-treated HER2+ MBC (2nd line MBC), like we received from the FDA in February. This was the EMILIA trial. Both were filed in August of 2012, same data to both regulatory agencies, also filed in Japan I believe around the same time. Chugai is the Roche partner there.
CH, this trading pattern in IMGN has been repeated several times, take a look at the charts. after a large rise, there are 3-5 days of heavy selling, followed by a short 1-2 week period of consolidation, then the rise resumes and it's back to either a new high, or near the high. I think most of the damage is done. Absent any news, next is consolidation, which is good for traders then the rise. OK, back to the fundamentals now.